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Abstract
Cystic fibrosis is one of the most common autosomal recessive hereditary diseases in the Caucasian population, with an incidence 
of 1:2000 to 1:3500 liveborns. More than 1000 mutations have been described with the most common being F508del. It has a 
prevalence of 23-55% within the Brazilian population. The lack of population-based studies evaluating the incidence of cystic 
fibrosis in São Paulo State, Brazil, and an analysis concerning the costs of implantation of a screening program motivated the 
present study. A total of 60,000 dried blood samples from Guthrie cards obtained from April 2005 to January 2006 for neonatal 
screening at 4 reference centers in São Paulo State were analyzed. The immunoreactive trypsinogen (IRT)/IRT protocol was 
used with the cut-off value being 70 ng/mL. A total of 532 children (0.9%) showed IRT >70 ng/mL and a 2nd sample was col-
lected from 418 (80.3%) of these patients. Four affected children were detected at two centers, corresponding to an incidence 
of 1:8403. The average age at diagnosis was 69 days, and 3 of the children already showed severe symptoms of the disease. 
The rate of false-positive results was 95.2% and the positive predictive value for the test was 8%. The cost of detecting an 
affected subject was approximately US$8,000.00 when this cystic fibrosis program was added to an existing neonatal screen-
ing program. The present study clearly shows the difficulties involved in cystic fibrosis screening using the IRT/IRT protocol, 
particularly in a population with no long-term tradition of neonatal screening.
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Cystic fibrosis (CF) is one of the most common au-
tosomal recessive hereditary diseases in the Caucasian 
population, with an estimated incidence of 1:2000 to 1:3500 
liveborns (1). It is a result of mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene lo-
cated on chromosome 7 (2-4). More than 1000 mutations 
have been described (5), the most common being F508del, 
which shows a prevalence of 70% among Caucasians (6) 
and of approximately 23-55% among Brazilians (7). A recent 
study using a two-tier survey design in five Brazilians States 
(Minas Gerais, São Paulo, Paraná, Santa Catarina, and 
Rio Grande do Sul) suggested that nearly 48% of the CF 
alleles carry the F508del mutation and estimated that the 
disease incidence for Brazilians of European descent is 1 
in 7576 live births. In addition, the investigators suggested 
that the CF prevalence in different parts of Brazil may differ 
by almost 20-fold (from 1 in 32,258 live births in São Paulo 
to 1 in 1587 in Rio Grande do Sul) (8).
Newborn screening for CF is expanding rapidly both in 
the US and in many European countries (9,10). In Brazil, 
only 3 of the 27 states have programs for CF screening. 
The lack of population-based studies about its incidence 
in the State of São Paulo, Brazil, as well as the need for 
a detailed analysis concerning the difficulties and costs of 
implanting such a program as part of the Neonatal Screen-
ing Program, motivated the present study. 
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Material and Methods
Dried blood spots (Guthrie cards) were collected on 
Schleicher and Schuell 903 filter paper from 60,000 neo-
nates as part of routine neonatal screening for hypothy-
roidism, phenylketonuria, and hemoglobinopathies in São 
Paulo State, Brazil. This sample represented 9.77% of all 
liveborns in 1 year in the State of São Paulo. This was a 
collaborative study involving 4 neonatal screening centers 
in São Paulo State, Brazil: Center 1, University Hospital 
of the School of Medicine of Ribeirão Preto, USP; Center 
2, University Hospital of Campinas (UNICAMP); Center 3, 
Laboratory of the “Associação de Pais e Amigos dos Ex-
cepcionais (APAE)”, a private non-profit institution for the 
protection of mentally retarded children, in Bauru; Center 
4, Santa Marcelina’s Hospital Laboratory in São Paulo city. 
After routine analysis at these centers, the samples were 
mailed to Center 1 for the measurement of immunoreactive 
trypsinogen (IRT). All samples from April 2005 to January 
2006 were included. 
Discs measuring 3 mm in diameter punched from the 
dried blood spot samples were assayed for IRT with a 
commercially available kit (DELFIA™). Interassay and intra-
assay precision determined by the coefficients of variation 
was 5.9 and 6.7% at concentrations of 20.0 and 26.4 ng/
mL, respectively. The screening strategy used was the 
IRT/IRT protocol, with the recommendation to collect the 
second IRT (IRT2) sample at age 3 to 4 weeks, since IRT 
levels are reduced after 30 days of life (11). Infants with a 
first IRT (IRT1) value greater than 70 ng/mL were recalled 
for IRT2 analysis. The cut-off value for IRT2 was the same 
as used for IRT1, i.e., 70 ng/mL.
All infants with positive IRT2 results were referred to 
Center 1 or Center 2 for clinical evaluation and for the mea-
surements of sweat electrolytes using the Gibson-Cooke 
pilocarpine iontophoresis sweat-chloride test on the fore-
arms (12). Chloride was measured spectrophotometrically 
by the modified method of Scharles and Scharles (13) using 
a commercial kit (Labtest Diagnóstica S.A., Brazil). All tests 
were performed by the same technician.
A sweat chloride concentration higher than 60 mEq/L 
was considered to be diagnostic of CF. Results between 
30 and 59 mEq/L were considered to be borderline and a 
second sweat test was carried out.
Results are reported as means ± SD of the absolute 
values and also as median. To calculate the sample size, 
a significant level of 0.05, an error of 0.008% and a preva-
lence of the disease of about 1/9000 were considered. To 
calculate positive and negative predictive values a 1/9000 
disease prevalence was considered. The SAS software 
program was used to create a database and to analyze 
the data. 
The study was approved by the Institutional Review 
Board and all mothers gave written informed consent during 
the second IRT blood collection.
Results
A total of 60,000 neonates were screened with the IRT/
IRT protocol between April 2005 and January 2006. The 
median infant age at the time of the neonatal screening test 
ranged from 2 to 7 days at the various centers, with 73.3, 
80.1, 56.2, and 95.6% being tested during the first week 
of life at Centers 1, 2, 3, and 4, respectively. The test was 
carried out earlier (2 days) at Center 4 because almost all 
samples were collected before the patients were discharged 
from the hospital.
Of the neonates screened, 59,468 had an IRT1 con-
centration below the decision level and were reported as 
“cystic fibrosis not indicated”. In 532 neonates (0.9%), the 
IRT1 was above the cut-off value (70 ng/mL). Of these, 
418 (80.3%) were submitted to the 2nd test. Centers 1 
and 2 were able to obtain the return of almost all infants 
for the 2nd collection (95.1 and 95.9%, respectively), while 
the return rates at Centers 3 and 4 were 69.3 and 57.2%, 
respectively. 
Means ± SD, median and range of children’s age (days 
old) on the occasion of the second IRT test (IRT2) were 
30.6 ± 13.3, 28 (10-99) days at Center 1; 48.5 ± 25.5, 42 
(16-175) days at Center 2; 68.5 ± 20.4, 68.5 (29-138) days 
at Center 3, and 65.8 ± 32, 62.5 (12-168) days at Center 4. 
Only Center 1 was able to perform the second collection for 
IRT2 within an adequate time interval, i.e., at a mean infant 
age of 30.6 days and a median of 28 days. The remaining 
centers obtained the 2nd collection at a mean infant age 
of more than 45 days, with Centers 3 and 4 showing the 
worst performance, i.e., with medians of 62.5 and 68.5 days, 
respectively. The main reason for failure to return for IRT2 
at Centers 3 and 4 was due to the fact that the infants were 
asymptomatic and thus less importance was attributed to 
the test by the mothers or the pediatricians. Additionally, 
there was difficulty in locating infants with elevated IRT1 in 
the city of São Paulo (Center 4) due to a change in address 
or to an incorrect address. On this basis, no affected infant 
was diagnosed at these centers.
At Center 1, 11 infants presented altered IRT1 and 
IRT2 (6 of them after collections made within less than 30 
days). Two infants whose IRT2 tests were performed at 
24 and 48 days presented a positive sweat chloride test 
(99.6 and 108.5 mEq/L, respectively), confirming the pres-
ence of the disease. In order to detect all affected infants, 
those who were submitted to the 2nd IRT collection at this 
center after more than 30 days (N = 64) and those who did 
not return for the 2nd collection (N = 9) were summoned 
for the sweat chloride test. No other altered results were 
observed in addition to the 2 infants mentioned above. Two 
other infants belonging to Center 2 also presented altered 
sweat chloride test results, confirming the presence of 
the disease. Clinical data and the results of the tests are 
presented in Table 1. 
Analysis of the data from the individual centers that had 
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the most success in recalling patients for the 2nd IRT col-
lection (Centers 1 and 2, N = 33,433) revealed that of 282 
infants (0.83%) with an altered IRT1, 269 (95.3%) returned 
for the 2nd IRT collection. Of the recalled infants, 13 (4.83%) 
had a 2nd IRT result above the cut-off point (70.0 ng/mL), 
which represents a 95.2% rate of false-positive results at 
first measurement. Regarding the false-negative results, to 
date, 1 year and 11 months after the end of the collections, 
no child has been diagnosed with the disease at Centers 
1 and 2. Based on the results of these two centers, the 
incidence of the disease was 1:8403.
The estimated laboratory cost of detecting a positive 
case by adding this screening strategy to an existing neo-
natal screening program was US$8,000.00/child. This is 
based on the costs of reagents and laboratory staff.
Discussion 
Neonatal screening for CF became available in 1979 
when Crossley et al. (14) developed a method for IRT de-
termination in blood samples collected on Guthrie cards in 
New Zealand. In recent years, there has been an increase 
in the number of CF screening programs around the world 
(9). However, newborn screening for CF has been hotly 
debated because of the lack of a definitive test for CF 
screening (15) and some concerns about the long-term 
benefits of these programs (10,16-23). 
After cloning of the CF gene in 1989 (2-4) and the 
availability of a molecular diagnosis for the disease, other 
questions arose: 1) Would the detection of carriers of the 
mutation, when this analysis is used for diagnosis, involve 
some drawback for these individuals? 2) Since approxi-
mately 5% of the infants identified have a doubtful sweat 
test (concentrations of 30-40 mmol/L) and “mild” mutations, 
how many of these individuals will have health problems and 
require the same treatment as affected individuals? 
In view of these considerations, in 2003, the United 
State Centers for Disease Control and Prevention (CDC) 
published recommendations for the screening of CF (24). 
In that report, the CDC concluded that CF screening is 
justifiable and should be considered by each state based 
on the evidence of a moderate benefit and low risk of harm, 
although recognizing that each state should consider re-
sources available and competing public priorities. 
The IRT method determination is the starting point 
for neonatal screening in all protocols used thus far (25), 
although IRT levels can be elevated in various situations 
not related to CF (11). The original IRT/IRT screening 
protocol was adopted in the present study in view of the 
ethnic heterogeneity of the Brazilian population and the 
need to investigate various mutations, despite the known 
large number of false-positive results (26,27). This protocol 
involves two blood collections, with the first ideally to be 
carried out during the first week of life, and the second, 
3-4 weeks later (11). The increase in IRT during the first 
week is a sensitive, but not specific, test for CF, and a 
Table 1. Clinical characteristics of patients with cystic fibrosis detected by neonatal screening in São Paulo State, Brazil.
Patient A Patient B Patient C Patient D
Ethnic origin Italian, Black Portuguese, Black Black, Indian Spanish, Black
Gender Male Female Male Female
Age at diagnosis 62 days 75 days 100 days 42 days
Initial diagnosis Milk allergy Milk allergy - -
Onset of symptoms Since birth Since birth Since birth 2 months
Symptoms Increased stool frequency, 
fatty stools, difficulty in 
gaining weight, dyspnea 
and cough
Increased stool 
frequency, vomiting, 
cough, difficulty in 
gaining weight
Difficulty in gaining 
weight, dehydration (3 
hospitalizations) after 
the 1st month of life
Nasal 
obstruction and 
gastroesophageal 
reflux
Birth weight/length 2.550 g/45 cm 3345 g/49 cm 2840 g/48 cm 3345 g/48 cm
Weight at diagnosis/length 2.675 g/49.5 cm 3315 g/55 cm 4380 g/54 cm 4680 g/56 cm
Heart rate (bpm) 120 140 120 120
IRT1 (ng/mL)/child’s age 205/4 days old 113/3 days old 143/2 days old 258/2 days old
IRT2 (ng/mL)/child’s age 97.9/48 days old 85.2/24 days old 74.6/18 days old 103/24 days old
Chloride in sweat (pmol/L)/child’s age 108.5/62 days old 99.6/75 days old 114.1/100 days old 84.6/42 days old
IRT = immunoreactive trypsinogen.
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second collection prevents an unnecessary definitive test 
for the disease (sweat chloride test) in a large number of 
infants (11). 
In the present study, the first collection occurred in the 
first week of life in only 75.4% of cases. These data indi-
cate the need for improvement of the Neonatal Screening 
programs at 3 of the 4 centers participating in the study 
since, with the exception of Center 4, the percentage of 
infants with delayed collections was high. These delayed 
collections, as well as laboratory routines at the screening 
centers before the samples were sent to Center 1 for IRT 
measurements, contributed to the delayed recalls for IRT2, 
except for the two University Hospital Centers (1 and 2) 
where mean and median ages were more adequate. Fail-
ure to come to the center for the 2nd collection was due to 
the following reasons: 1) on many occasions, the mothers 
although having been informed about the program, did not 
give consent for the 2nd collection because the child was 
doing well and gaining weight adequately, 2) the pediatri-
cian failed to stimulate the second test, considering it to be 
unnecessary, 3) many infants could not be located, espe-
cially in the city of São Paulo, due to a change of address 
or incorrect telephone numbers, difficulties that have also 
been reported in other studies (28-30).
Lack of information about the disease and low effort by 
health professionals involved in neonatal care contributed 
to inadequate screening times, indicating that the introduc-
tion of such a complex program would require great effort 
in providing adequate information to the professionals 
involved. The methods used to improve information in 
the current study, including letters sent to health units, to 
pediatricians, and an educational symposium, were not 
sufficient to obtain a better performance despite the careful 
monitoring of all the phases of the study. A recent report 
about CF screening in New York city (30) showed that 690 
infants residing in the metropolitan area were lost to follow-
up. The authors explicitly stated that many doctors did not 
refer the infants with positive results to the sweat chloride 
test and that the State of New York was investing in primary 
education in order to obtain more adhesion to the program. 
This observation demonstrates that these difficulties occur 
even in countries where substantial resources are available 
for public health policies.
The cut-off point for IRT1 has been a subject of debate 
since the number of false-positive and false-negative re-
sults depends on this value. We have used 70.0 ng/mL, 
as adopted by the 3 regional programs currently active in 
Brazil (29,31,32). The highest sensitivity previously reported 
with the IRT/IRT protocol was 86-87% by using either a 
fixed cut-off point that would permit the recall of 1% of the 
infants, or a variable cut-off point based on the use of the 
percentile of the highest values (11,27). 
In the present study, 41.9% of the infants had had the 
2nd collection after more than 45 days of life. The difficulty 
in obtaining the 2nd sample has been reported to be high 
(22% in the Colorado study, USA) (28). The performance 
of Centers 1 and 2 in the recall of infants with altered IRT1 
permitted obtaining a 2nd collection from 95.1 and 95.9% of 
infants, respectively, at an age of less than 45 days for 90.8 
and 59.6% of the infants. On the basis of the detection of 
only 4 affected infants at these two Reference Centers, the 
incidence of CF was 1:8403 liveborns, values comparable 
to those obtained in the States of Paraná (1: 9.520) (29), 
Santa Catarina (1:8776) (32), and Minas Gerais (1:9115) 
(31) using a similar methodology. Three of the diagnosed 
infants already presented symptoms of the disease and 
had been hospitalized when the sweat chloride test was 
performed for diagnostic confirmation. Similar results were 
observed by Alvarez et al. (33), who reported that 72.7% of 
the patients presented some type of clinical manifestation 
before 6 months of age.
A recent report regarding CF screening in the State of 
Minas Gerais, Brazil, involving 455,755 infants showed 53 
affected infants but the mean age at diagnosis was late, 
(51.4 days), when 23.3% of the infants had already been 
admitted to ICUs, 50% had anemia, and 60% hypoalbumin-
emia, and 1 death had occurred (31). In the State of Santa 
Catarina, Brazil, the screening of 386,183 infants detected 
44 affected patients, with a mean time at diagnosis of 64 
days, 21 (47.7%) of them presented malnutrition, another 
25 presented steatorrhea, and 4 deaths occurred (32). 
Only 1 infant benefited directly from neonatal screening 
in the present study. She did not present symptoms of the 
disease when the sweat chloride test was carried out at 42 
days of age. It is necessary to emphasize the importance 
of performing the chloride test within a few days after two 
altered IRT results (34) since a late scheduling for the 
test in patient No. 3 caused three hospitalizations due to 
dehydration. 
To make sure that no affected infant would go unde-
tected, Center 1 continued recalling all infants whose 2nd 
IRT collections had been obtained at more than 30 days of 
age, regardless of whether the results were normal or not, 
and the sweat chloride test was applied to all of them. Thus, 
a total of 77 infants were tested but the disease was not 
identified in any of them. The rate of false-positive results 
was high (95.2%) considering the results of the first altered 
IRT, and comparable to that obtained in other studies (29). 
In the present study, an 8%-positive predictive value was 
demonstrated. 
Considering the decline of IRT value with time, the 
overlap of IRT values between infants with and without 
CF and the test sensitivity (87%), Rock et al. in 1990 (11) 
concluded that the use of the IRT/IRT protocol is not an 
acceptable strategy for neonatal CF screening. On this 
basis, most of the centers that were using CF screening 
by IRT/IRT protocol started to use the molecular biological 
analysis of blood samples collected from patients with an 
altered IRT1 (26,35,36). In introducing the IRT/DNA proto-
col, the choice of the mutations to be studied will depend 
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on previous knowledge of those that are more prevalent in 
the population under study. In the State of Wisconsin, USA, 
analysis of the F508 del mutation started being performed 
because it is the most prevalent mutation, occurring in 70% 
of affected patients. This approach has permitted diagnostic 
sensitivity to increase to 94% (37). 
In Brazil, in view of the genetic diversity of the population 
(8,38), CF screening by searching for the F508del mutation 
would not be cost-effective, while searching for the more 
frequent mutations F508del, G542X, G551D, R553X, and 
N1303K would probably result in the detection of only 
one mutated allele and would not permit a diagnosis. On 
this basis, screening by genetic analysis would have to 
be planned to detect a larger number of mutations since, 
as is the case for regions of Southern Europe, especially 
Spain and Italy, only the search for at least 20 mutations 
would permit the detection of approximately 70% of affected 
individuals (9). Thus, the disadvantage of using IRT/DNA 
in Brazil may be associated with diagnostic failure due to 
the ethnic heterogeneity of our population. A larger number 
of gene carriers would also be identified. This will require 
careful genetic counseling and the development of policies 
for the testing of their relatives. 
The cost of detecting patients with CF was approximately 
US$8,000.00/child when the IRT/IRT program was added 
to an existing neonatal screening program. Similar values 
were suggested by Reis and Damaceno in 1998 (39). 
The results of the present study using IRT/IRT methodol-
ogy are similar to those obtained at other screening centers. 
Despite the intense effort, the investigation protocol was only 
moderately successful, considering that delayed diagnoses 
were documented (between 2 and 3 months). In addition, 
the low specificity of the test and the high percentage of 
false-positive results generated great anxiety among the 
parents until the hypothesis of the disease was excluded.
Analysis of the medical records of CF patients diagnosed 
on a clinical basis at Center 1 (Fernandes MIM, unpublished 
data) showed that age at diagnosis ranged from 1 month 
to 28 years for 68 patients who were followed. Sixty-three 
percent of the patients presented clinical symptoms early, 
before 3 months of life. In that series, a diagnosis was con-
firmed before 4 months in most cases, with the median age at 
diagnosis for the 21 infants presenting digestive symptoms 
since birth being 3 months (range: 2 to 24 months). Com-
parison of these results with those obtained in the present 
study suggests that diagnosis was made approximately 1 
month earlier with screening, a goal that might be reached 
by simply promoting better awareness of the disease. Un-
der ideal conditions, a neonatal screening program would 
certainly reduce the time for diagnosis even more, since 
these are determinant factors for the success of a program 
using the IRT/IRT protocol. For this to occur, it would be 
necessary to improve the program used, with sample col-
lection during the 1st week of life for all infants. 
In conclusion, under the conditions of the present in-
vestigation, we were not able to demonstrate an evident 
advantage of CF screening using the IRT/IRT protocol. A 
major improvement of sample collections and timing would 
be necessary in order to be able to recommend neonatal 
screening for CF using this protocol as the only public health 
strategy. In addition, increased medical education with pe-
diatricians being trained to identify the signs and symptoms 
for an early recognition of the disease, as well as raising 
population awareness about the disease, would increase 
the chances for an earlier diagnosis of the disease. 
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